Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Min Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3971-9130; OpenAlex author ID A5100400736, A5137157871. Sources: OpenAlex.

Their work

Papers
42 (first author 3, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
147
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 2 papers · 2014: 2 papers · 2015: 4 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers · 2022: 7 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 42

  1. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  2. Spatial evolution of a cachexia-promoting microenvironment in pancreatic cancer. Last author DOI 10.1016/j.cell.2026.09.012↗
  3. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Co-author DOI 10.1038/s41467-026-75132-3↗
  4. Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5716↗
  5. Glutaminase 2-Mediated Yes Associated Protein 1 Glutamylation Facilitates Immune Evasion in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2025.02.029↗
  6. Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy. Last author DOI 10.1158/1078-0432.ccr-24-4368↗
  7. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Last author DOI 10.1016/j.ccell.2024.03.009↗
  8. Replication stress identifies novel molecular classification associated with treatment outcomes in pancreatic cancer. Last author DOI 10.1016/j.pan.2022.11.008↗
  9. Pancreatic Cancer: Targeted Therapy Holds the Promise. First author DOI 10.1016/j.ebiom.2021.103755↗
  10. Attenuating DNA damage response and immunosuppression radiosensitizes pancreatic cancer. Last author DOI 10.1016/j.ebiom.2022.103822↗
  11. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  12. A Novel Translational Activation of HIF1α Promotes Pancreatic Cancer Growth Through Glycolytic Reprogramming. Last author DOI 10.1053/j.gastro.2022.01.040↗
  13. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2022.02.017↗
  14. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2022.06.058↗
  15. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-1083↗
  16. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Last author DOI 10.1016/j.ebiom.2021.103271↗
  17. Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.tranon.2021.101139↗
  18. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2020.12.077↗
  19. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Last author DOI 10.1053/j.gastro.2019.10.038↗
  20. A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma. First author DOI 10.1186/s12916-020-01620-y↗
  21. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  22. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cance… Co-author DOI 10.1155/2019/6402925↗
  23. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  24. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  25. Pancreatic cancer: challenges and opportunities. Last author DOI 10.1186/s12916-018-1215-3↗
  26. Editorial - Special issue on Fighting Pancreatic Cancer. Co-author DOI 10.1016/j.canlet.2017.04.009↗
  27. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Co-author DOI 10.1158/1078-0432.ccr-14-3382↗
  28. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  29. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Last author DOI 10.1016/j.canlet.2015.04.009↗
  30. ZIP4 silencing improves bone loss in pancreatic cancer. Last author DOI 10.18632/oncotarget.4667↗
  31. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancrea… Co-author DOI 10.2147/dddt.s73689↗
  32. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Co-author DOI 10.1186/1476-4598-13-187↗
  33. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Co-author DOI 10.18632/oncotarget.1890↗
  34. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Co-author DOI 10.3892/ijo.2013.1780↗
  35. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Co-author DOI 10.3892/ijo.2013.1901↗
  36. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Last author DOI 10.1016/j.canlet.2012.05.013↗
  37. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. Last author DOI 10.1111/j.1582-4934.2011.01478.x↗
  38. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Co-author DOI 10.3892/ijo.2012.1613↗
  39. Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy. Last author DOI 10.7573/dic.212244↗
  40. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Co-author DOI 10.1002/cncr.25629↗
  41. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer. Co-author DOI 10.1097/cji.0b013e318209ee72↗
  42. Overcoming drug resistance in pancreatic cancer. Last author DOI 10.1517/14728222.2011.566216↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Courtney W. Houchen · 17 shared papers, 2015–2026 · strength 3.51
  2. Zhijun Zhou · 10 shared papers, 2020–2026 · strength 1.74
  3. Jingxuan Yang · 17 shared papers, 2011–2026 · strength 1.53
  4. Mingyang Liu · 7 shared papers, 2019–2024 · strength 0.88
  5. Xiuhui Shi · 6 shared papers, 2021–2024 · strength 0.80
  6. Yuqing Zhang · 3 shared papers, 2021–2025 · strength 0.67
  7. Hao Yuan · 2 shared papers, 2025–2026 · strength 0.57
  8. Lei Zheng · 2 shared papers, 2024–2026 · strength 0.38
  9. Yuqing Zhang · 2 shared papers, 2022 · strength 0.38
  10. Hanxiang Zhan · 3 shared papers, 2020–2021 · strength 0.30
  11. Qun Chen · 1 shared paper, 2025 · strength 0.30
  12. Kuirong Jiang · 1 shared paper, 2025 · strength 0.30
  13. Qiushi Lin · 2 shared papers, 2019–2026 · strength 0.30
  14. Xuewei Bai · 2 shared papers, 2019–2026 · strength 0.30
  15. Lianxin Liu · 2 shared papers, 2019–2026 · strength 0.30
  16. Rui Kong · 2 shared papers, 2019–2026 · strength 0.30
  17. Katsuya Nagaoka · 2 shared papers, 2019–2026 · strength 0.30
  18. Xiaoqun Dong · 2 shared papers, 2019–2026 · strength 0.30
  19. Jack R. Wands · 2 shared papers, 2019–2026 · strength 0.30
  20. Kosuke Ogawa · 2 shared papers, 2019–2026 · strength 0.30
  21. Le Li · 2 shared papers, 2019–2026 · strength 0.30
  22. Howard P. Safran · 2 shared papers, 2019–2026 · strength 0.30
  23. Xianjun Yu · 7 shared papers, 2011–2019 · strength 0.28
  24. Shaobo Zhang · 1 shared paper, 2026 · strength 0.26
  25. Haoran Qi · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.